title: Ovulation of the preovulatory follicle originating from the first-wave dominant follicle leads to formation of an active corpus luteum.
abstract: The objective of our study was to compare the characteristics of the corpus luteum (CL) formed after ovulation of the dominant follicle (DF) of the first follicular wave (W1) and those of the CL formed after ovulation of the DF of the second (induced) follicular wave (W2). Non-lactating Holstein cows were used for this study. In Experiment 1, cows were treated with PGF2α and GnRH on days 6 and 8 (day 0 = day of follicular wave emergence) for W1 (n = 6) and W2 (n = 6), respectively. Dominant follicles were aspirated on day 9 to quantify the amounts of mRNA (VEGF120, VEGF164, FGF-2, StAR, P450-scc and 3β-HSD) in granulosa cells (GC). In Experiment 2, the size and blood flow area of the CL formed after ovulation of the DF in W1 (W1CL; n = 6) and W2 (W2CL; n = 6) (the day of DF ovulation in W1 and W2 was day 10) were evaluated on days 12, 15, 18 and 21. The plasma P4 concentration was measured on days 10 to 21. The amounts of VEGF164, P450-scc and 3β-HSD mRNA were higher (P < 0.05) in the DF in W1, and those of VEGF120,FGF-2 and StAR mRNA tended to be higher (P < 0.1) in the DF in W1. The size of the CL was greater in the W1CL on days 15, 18 and 21. The blood flow area of the CL was greater in the W1CL on days 12 and 15. The plasma P4 concentrations were higher in the W1CL. These results indicate that the CL formed after ovulation of the DF in W1 was greater in terms of size, blood flow and plasma P4 concentration.
authors.affiliation: The United Graduate School of Veterinary Sciences, Gifu University, Gifu 501-1193, Japan.
authors.forename: Ryotaro
authors.initials: R
authors.lastname: Miura
authors.forename: Shingo
authors.initials: S
authors.lastname: Haneda
authors.forename: Motozumi
authors.initials: M
authors.lastname: Matsui
mesh_terms: D000818:Animals; D017849:Animals, Inbred Strains; D002417:Cattle; D003338:Corpus Luteum / Q000098:blood supply / Q000166:cytology* / Q000000981:diagnostic imaging / Q000378:metabolism; D018592:Cross-Over Studies; D015237:Dinoprost / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology; D005498:Follicular Phase / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000494:pharmacology; D006107:Granulosa Cells / Q000166:cytology / Q000000981:diagnostic imaging / Q000378:metabolism; D007564:Japan; D006080:Ovarian Follicle / Q000098:blood supply / Q000166:cytology* / Q000000981:diagnostic imaging / Q000378:metabolism; D010060:Ovulation / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D010062:Ovulation Induction / Q000662:veterinary; D011374:Progesterone / Q000097:blood / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012039:Regional Blood Flow / Q000187:drug effects; D018615:Ultrasonography, Doppler, Color / Q000662:veterinary
chemical_list: D005300:Fertility Agents, Female; D012333:RNA, Messenger; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D015237:Dinoprost; C010714:dinoprost tromethamine; C009936:fertirelin